IL157540A0 - N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof - Google Patents

N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof

Info

Publication number
IL157540A0
IL157540A0 IL15754002A IL15754002A IL157540A0 IL 157540 A0 IL157540 A0 IL 157540A0 IL 15754002 A IL15754002 A IL 15754002A IL 15754002 A IL15754002 A IL 15754002A IL 157540 A0 IL157540 A0 IL 157540A0
Authority
IL
Israel
Prior art keywords
aryl
arylethenesulphonamides
therapeutic uses
agents
useful
Prior art date
Application number
IL15754002A
Other languages
English (en)
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc filed Critical Univ Temple
Publication of IL157540A0 publication Critical patent/IL157540A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
IL15754002A 2001-02-28 2002-02-28 N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof IL157540A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27198501P 2001-02-28 2001-02-28
PCT/US2002/005979 WO2002067865A2 (en) 2001-02-28 2002-02-28 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
IL157540A0 true IL157540A0 (en) 2004-03-28

Family

ID=23037924

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15754002A IL157540A0 (en) 2001-02-28 2002-02-28 N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
IL157540A IL157540A (en) 2001-02-28 2003-08-21 Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157540A IL157540A (en) 2001-02-28 2003-08-21 Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation

Country Status (11)

Country Link
US (1) US6646009B2 (enExample)
EP (1) EP1379508B9 (enExample)
JP (1) JP4171656B2 (enExample)
KR (1) KR100850330B1 (enExample)
AT (1) ATE479657T1 (enExample)
AU (1) AU2002306604B2 (enExample)
CA (1) CA2439255C (enExample)
DE (1) DE60237512D1 (enExample)
DK (1) DK1379508T3 (enExample)
IL (2) IL157540A0 (enExample)
WO (1) WO2002067865A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667346B2 (en) * 2001-02-28 2003-12-23 Temple University - Of The Commonwealth System Of Higher Education Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
US8664272B2 (en) 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
SG10201506526QA (en) * 2007-12-21 2015-09-29 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
WO2010144959A1 (en) * 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
WO2013039985A2 (en) * 2011-09-12 2013-03-21 The Johns Hopkins University Serine protease inhibitors
US9730913B2 (en) 2011-10-13 2017-08-15 The Johns Hopkins University High affinity beta lactamase inhibitors
CA2885217C (en) 2012-09-20 2019-10-08 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
JP2022517797A (ja) * 2019-01-17 2022-03-10 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531367A (en) * 1947-07-15 1950-11-21 Sharp & Dohme Inc N-(substituted sulfonyl)-aminobenzoic acids
DE2118493C3 (de) 1971-04-16 1980-04-30 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Aminostilbenen
US4035421A (en) 1976-03-19 1977-07-12 Morton-Norwich Products, Inc. N-(3,4,-dichlorophenyl)-2-phenylethenesulfonamide
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
ZA915371B (en) 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
JPH04202173A (ja) * 1990-11-30 1992-07-22 Zeria Pharmaceut Co Ltd スルホンアミド誘導体及びそれを含有する5―リポキシゲナーゼ阻害剤
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Il−8受容体拮抗剤
NZ331941A (en) * 1996-02-22 2000-04-28 Tularik Inc Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
US6191170B1 (en) * 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DK1115701T3 (da) 1998-09-23 2003-06-23 Tularik Inc Arylsulfonanilidurinstoffer
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives

Also Published As

Publication number Publication date
CA2439255A1 (en) 2002-09-06
WO2002067865A2 (en) 2002-09-06
KR100850330B1 (ko) 2008-08-04
KR20030086279A (ko) 2003-11-07
WO2002067865A3 (en) 2003-03-20
JP2004530655A (ja) 2004-10-07
DE60237512D1 (de) 2010-10-14
ATE479657T1 (de) 2010-09-15
EP1379508A4 (en) 2005-12-28
AU2002306604B2 (en) 2007-09-13
US20020165412A1 (en) 2002-11-07
DK1379508T3 (da) 2011-01-03
US6646009B2 (en) 2003-11-11
EP1379508A2 (en) 2004-01-14
EP1379508B9 (en) 2011-02-09
IL157540A (en) 2010-11-30
JP4171656B2 (ja) 2008-10-22
EP1379508B1 (en) 2010-09-01
CA2439255C (en) 2011-01-04

Similar Documents

Publication Publication Date Title
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
BG106586A (en) Pyrazolopyramidines as therapeutic agents
DE60112974D1 (en) Carbolinderivate
DK1200412T3 (da) Antiproliferative imidazolforbindelser
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
GEP20084488B (en) Use of therapeutic agents for treating pain
SE9904505D0 (sv) Novel compounds
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
MXPA03010761A (es) Combinaciones farmaceuticas.
AP2002002616A0 (en) Antidibetic agents
DE60216233D1 (en) Carbolinderivate
ATE233754T1 (de) Diphenyl-piperidin derivate
EP1450803A4 (en) NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MY138826A (en) 2,7-substituted indoles
SE0101038D0 (sv) Novel compounds
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
IL166730A0 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-Ä1,3,4-oxadiazol-2-ylÜphenyl)pyridine-3-sulphonamide as an anticancer agent